KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.

Andreas Reif, Bernhard T Baune, Jozefien Buyze, Anthony J Cleare, Shaun Johnson, Yerkebulan Kambarov, Nigel Olisa, Falk Schuster, Christian von Holt, Tamara Werner-Kiechle, Eduard Vieta

Eur Psychiatry 68(1) e156

PMID41084764
PMCIDPMC12646121
DOI10.1192/j.eurpsy.2025.10123
发表日期2025-10-14
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Clinical response and remission may not fully reflect patient priorities in treatment-resistant depression (TRD). Health-related quality-of-life (HRQoL) outcomes should be assessed to comprehensively capture treatment benefits. METHODS: ESCAPE-TRD (NCT04338321) was a 32-week randomized, phase IIIb trial comparing esketamine nasal spray (NS) versus quetiapine extended release (XR), both alongside an ongoing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor, in patients with TRD. Symptom and HRQoL improvements were assessed using the Patient Health Questionnaire-9 (PHQ-9), 36-Item Short Form Survey (SF-36), Quality of Life in Depression Scale (QLDS), and EuroQoL 5-Dimension 5-Level (EQ-5D-5L) measures. RESULTS: Esketamine NS-treated patients (N=336) reached PHQ-9 remission (score ≤4) quicker than quetiapine XR-treated patients (N=340), and more had remission by Week 32 (34.5% vs. 18.2%; odds ratio [OR]: 2.39 [1.67, 3.41], p<0.0001). "Role Emotional", "Mental Health", and "Social Functioning" SF-36 domains showed significantly greater improvements in esketamine NS-treated patients compared with quetiapine XR-treated patients at Week 32 (p<0.05), returning to levels close to general population norms. More esketamine NS-treated patients had a meaningful improvement in their QLDS score by Week 32 (60.7% vs. 41.8%; OR: 2.16 [1.59, 2.94], p<0.0001), and reached this improvement quicker than quetiapine XR-treated patients. Proportions of patients reporting an EQ-5D-5L score of 1 (no problems) were significantly higher across all domains with esketamine NS versus quetiapine XR at Week 32 (p<0.05). CONCLUSIONS: Esketamine NS produced superior improvements in HRQoL compared with quetiapine XR, indicating positive impacts on aspects of patients' lives that matter to them, alongside clinical symptoms of TRD.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 4

Figure 4. Time to a clinically meaningful improvement in QLDS. Full analysis set (includes all randomized patients). Patients discontinuing treatment were censored at an infinite (arbitrarily large) time and were assumed to never achieve clinically meaningful improvement. Time to first clinically meaningful improvement was defined as the first time a QLDS reduction of ≥8 points was reached. Shaded areas indicate 95% CIs. (A) Tested at a two-sided 0.05 significance level without adjustment for multiple testing. CI, confidence interval; ESK, esketamine; HR, hazard ratio; NS, nasal spray; QLDS, Quality of Life in Depression Scale; QTP, quetiapine; XR, extended release.

Figure_4A

Time to clinically meaningful improvement in QLDS

Figure 4 · Panel Figure_4A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Figure_4A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. ESCAPE-TRD study design. (A) Esketamine NS was dosed twice weekly (56 mg on Day 1, 56/84 mg from Day 4) from Weeks 1–4, weekly (56/84 mg) from Weeks 5–8, and weekly or Q2W (56/84 mg) from Weeks 9–32, all in addition to an ongoing SSRI/SNRI that elicited nonresponse at baseline. (B) Quetiapine XR was flexibly dosed and administered daily, starting at 50 mg on Days 1–2, 150 mg/day on Days 3–4, and 300 mg/day from Day 5 onwards, all in addition to an ongoing SSRI/SNRI that elicited nonresponse at baseline. NS, nasal spray; Q2W, every 2 weeks; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; XR, extended release.
非 KM Figure
Figure 2Figure 2. Proportion of patients achieving PHQ-9 remission over time. Full analysis set (includes all randomized patients). NRI was applied to treatment discontinuations. For patients who had a missing visit or a missing scale during a visit, but were still receiving study treatment, the missing score was imputed using LOCF. Tested at a two-sided 0.05 significance level without adjustment for multiple testing. Remission was defined as a PHQ-9 score ≤ 4. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. LOCF, last observation carried forward; NRI, nonresponder imputation; NS, nasal spray; PHQ-9, Patient Health Questionnaire-9; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; XR, extended release.
非 KM Figure
Figure 3Figure 3. LS mean SF-36v2 domain scores by treatment arm. Full analysis set (includes all randomized patients). Gray dotted lines represent 2009 US population norms. LS means were based on MMRM (based on observed cases; on-treatment visits), adjusted for age and number of prior treatment failures. * p < 0.05, ** p < 0.01, *** p < 0.001. ESK, esketamine; LS, least squares; MMRM, mixed model for repeated measures; NS, nasal spray; QTP, quetiapine; SF-36, 36-Item Short Form Survey; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; XR, extended release.
非 KM Figure
Figure 5Figure 5. Proportion of patients reporting EQ-5D-5L domain score of 1 (no problems) by treatment arm. Full analysis set (includes all randomized patients). NRI was applied to treatment discontinuations. For patients who had a missing visit or a missing scale during a visit, but were still receiving study treatment, the missing score was imputed using LOCF. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. EQ-5D-5L, EuroQoL 5-Dimension 5-Level; ESK, esketamine; LOCF, last observation carried forward; NRI, nonresponder imputation; NS, nasal spray; QTP, quetiapine; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; XR, extended release.
非 KM Figure